From: Post-recurrence survival analysis in patients with oligo-recurrence after curative esophagectomy
Variable | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
HR (95% CI) | p value | OR (95% CI) | p value | |
Age (≥ 60 vs. < 60 yrs) | 1.42 (0.77–2.61) | 0.259 | ||
Sex (male vs. female) | 0.05 (0.01–22.32) | 0.329 | ||
Charlson Comorbidity Index (≥1 vs. 0) | 1.18 (0.66–2.11) | 0.575 | ||
Performance status (1 vs. 0) | 1.25 (0.68–2.32) | 0.475 | ||
Tumor location (U/M third vs. L third/EGJ) | 1.26 (0.68–2.32) | 0.457 | ||
Tumor length | 0.97 (0.82 ~ 1.14) | 0.697 | ||
Neoadjuvant therapy (yes vs. no) | 0.96 (0.51–1.78) | 0.885 | ||
(y)p T stage (T3 vs. T0–2) | 2.03 (1.13–3.65) | 0.018 | 2.53 (1.36–4.71) | 0.003 |
(y)p N stage (N+ vs. N0) | 1.39 (0.77–2.49) | 0.270 | ||
Differentiation (poorly vs. well + moderately) | 1.88 (0.78–4.53) | 0.161 | ||
LVI (+ vs. -) | 1.32 (0.74–2.36) | 0.353 | ||
PNI (+ vs. -) | 1.71 (0.76–3.86) | 0.197 | ||
TRG (0 vs. 1–3) | 0.59 (0.24–1.41) | 0.244 | ||
CRM (involved or close vs. uninvolved) | 1.34 (0.63 ~ 2.84) | 0.440 | ||
Disease free interval (> 12 vs. ≤ 12 months) | 0.65 (0.36–1.17) | 0.149 | ||
Recurrence pattern | ||||
Distant vs. loco-regional | 0.81 (0.45–1.45) | 0.475 | ||
Lung (with vs. without) | 0.60 (0.31–1.15) | 0.125 | ||
Liver (with vs. without) | 1.02 (0.32–03.32) | 0.967 | ||
Bone (with vs. without) | 1.89 (0.450–7.88) | 0.382 | ||
Brain (with vs. without) | 2.69 (0.81–8.88) | 0.105 | ||
Pleural/Chest wall (with vs. without) | 0.95 (0.33–2.69) | 0.923 | ||
Cervical lymph node (with vs. without) | 0.85 (0.39–1.83) | 0.676 | ||
Mediastinum (with vs. without) | 2.79 (1.35–05.75) | 0.005 | 3.81 (1.76–8.26) | 0.001 |
Anastomosis (with vs. without) | 0.41 (0.10–1.78) | 0.236 | ||
Operation for recurrence (yes vs. no) | 0.61 (0.34 ~ 1.11) | 0.107 |